×
About 5,615 results

ALLMedicine™ Kidney Cancer Center

Research & Reviews  1,466 results

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
https://clinicaltrials.gov/ct2/show/NCT03793166

May 13th, 2022 - PRIMARY OBJECTIVE: I. To compare the overall survival (OS) in patients with metastatic renal cell cancer (RCC) treated with ipilimumab-nivolumab followed by either nivolumab versus cabozantinib-nivolumab. SECONDARY OBJECTIVES: I. To determine prog...

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
https://clinicaltrials.gov/ct2/show/NCT00050752

May 13th, 2022 - Background: Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare autosomal dominantly inherited disorder which confers susceptibility to develop cutaneous and uterine leiomyomas and renal cell carcinoma. HLRCC is caused by mutations i...

Association between circulating vitamin E and ten common cancers: evidence from large-s...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092790
BMC Medicine; Xin J, Jiang X et. al.

May 11th, 2022 - The association between vitamin E and cancer risk has been widely investigated by observational studies, but the findings remain inconclusive. Here, we aimed to evaluate the causal effect of circulating vitamin E on the risk of ten common cancers,...

Antitumor Plasma Cells Mature Within Tertiary Lymphoid Structures.
https://doi.org/10.1158/2159-8290.CD-RW2022-042
Cancer Discovery;

May 3rd, 2022 - Locally generated plasma cells initiate an antibody-mediated antitumor response in kidney cancer.

Association between cognitive impairment and oral anticancer agent use in older patient...
https://doi.org/10.1111/jgs.17826
Journal of the American Geriatrics Society; Pritchard JE, Wilson LE et. al.

May 3rd, 2022 - Kidney cancer is the fastest-growing cancer diagnosis in the developed world. About 16% of new cases are stage IV, which has a low five-year survival rate. Many patients with metastatic renal cell carcinoma (mRCC) are older and may have mild cogni...

see more →

Guidelines  11 results

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0001
Journal of the National Comprehensive Cancer Network : JN... Motzer RJ, Jonasch E et. al.

Jan 7th, 2022 - The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor hist...

KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and ...
https://doi.org/10.1016/j.kint.2020.06.046
Kidney International; Porta C, Bamias A et. al.

Nov 1st, 2020 - The association between kidney disease and cancer is multifaceted and complex. Persons with chronic kidney disease (CKD) have an increased incidence of cancer, and both cancer and cancer treatments can cause impaired kidney function. Renal issues ...

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.
https://doi.org/10.6004/jnccn.2020.0043
Journal of the National Comprehensive Cancer Network : JN... Motzer RJ, Jonasch E et. al.

Sep 5th, 2020 - The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, in...

Report From the International Society of Urological Pathology (ISUP) Consultation Confe...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289677
The American Journal of Surgical Pathology; Williamson SR, Gill AJ et. al.

Apr 7th, 2020 - Renal cell carcinoma (RCC) subtypes are increasingly being discerned via their molecular underpinnings. Frequently this can be correlated to histologic and immunohistochemical surrogates, such that only simple targeted molecular assays, or none at...

SEOM clinical guideline for treatment of kidney cancer (2017).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785618
Clinical & Translational Oncology : Official Publication ... Gallardo E, Méndez-Vidal MJ et. al.

Nov 15th, 2017 - The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized ...

see more →

Clinicaltrials.gov  157 results

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
https://clinicaltrials.gov/ct2/show/NCT03793166

May 13th, 2022 - PRIMARY OBJECTIVE: I. To compare the overall survival (OS) in patients with metastatic renal cell cancer (RCC) treated with ipilimumab-nivolumab followed by either nivolumab versus cabozantinib-nivolumab. SECONDARY OBJECTIVES: I. To determine prog...

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
https://clinicaltrials.gov/ct2/show/NCT00050752

May 13th, 2022 - Background: Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare autosomal dominantly inherited disorder which confers susceptibility to develop cutaneous and uterine leiomyomas and renal cell carcinoma. HLRCC is caused by mutations i...

Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery
https://clinicaltrials.gov/ct2/show/NCT04370509

Apr 28th, 2022 - PRIMARY OBJECTIVE: I. To determine the impact of pembrolizumab-based therapy on the composition, phenotype, and function of tumor-infiltrating immune cells (TIICs) in subjects with advanced renal cell carcinoma (RCC) undergoing cytoreductive nephr...

Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau
https://clinicaltrials.gov/ct2/show/NCT03907657

Apr 27th, 2022 - This is a pilot cross-sectional study that compares contrast enhanced ultrasound to conventional ultrasound and contrasted MRI. Any patient undergoing annual imaging screening is eligible, but the investigators will target inclusion of at least 10...

Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT02724878

Apr 12th, 2022 - This research study is a Phase II clinical trial. In this research the investigators are studying the combination of Atezolizumab with Bevacizumab. Participants will receive both vascular endothelial targeted therapy and immunotherapy. The FDA (th...

see more →

News  600 results

Renal Cell Carcinoma: Future Directions in Care
https://www.onclive.com/view/renal-cell-carcinoma-future-directions-in-care

May 2nd, 2022 - Transcript: Robert J. Motzer, MD: Two last quick points for you. Cabozantinib is 1 of our main go-to drugs for RCC [renal cell carcinoma]. It’s been proposed to be particularly effective for bone metastases, right? There were recent data for cabo...

Novel FSHR-Mediated CAR T Approach Under Exploration in Recurrent Ovarian Cancer
https://www.onclive.com/view/novel-fshr-mediated-car-t-approach-under-exploration-in-recurrent-ovarian-cancer

Apr 29th, 2022 - An investigative follicle-stimulating hormone receptor (FSHR)–mediated CAR T-cell technology (CER-T) is under exploration in patients with recurrent ovarian cancer as part of a phase 1 trial (NCT05316129) that is being conducted at Moffitt Cancer ...

Adjuvant Systemic Therapies for Patients With RCC Post-Nephrectomy
https://www.onclive.com/view/adjuvant-systemic-therapies-for-patients-with-rcc-post-nephrectomy

Apr 28th, 2022 - Tian Zhang, MD: Thinking about the recently approved adjuvant systemic therapies in this space in the postoperative setting, where patients are otherwise radiographically without evidence of disease, we had adjuvant sunitinib, which wasn’t often g...

Combination Sitravatinib and Nivolumab Boosts Outcomes in Advanced Kidney Cancer
https://www.medscape.com/viewarticle/972855

Apr 28th, 2022 - NEW YORK (Reuters Health) - In patients with advanced clear cell renal cell carcinoma (ccRCC), an optimal sitravatinib dose combined with a fixed dose of nivolumab improved outcomes in a phase 1-2 trial. "A surprising finding was that patients tre...

PROBE Trial in Progress to Understand Potential Benefits of Cytoreductive Nephrectomy in Metastatic RCC
https://www.onclive.com/view/probe-trial-in-progress-to-understand-potential-benefits-of-cytoreductive-nephrectomy-in-metastatic-rcc

Apr 20th, 2022 - As advanced renal cell carcinoma (RCC) treatment standards evolve, the phase 3 PROBE trial (NCT04510597) seeks to determine whether cytoreductive nephrectomy affects overall survival (OS) when combined with frontline immunotherapy, according to Ul...

see more →

Patient Education  12 results see all →